Compass Pathways Stock

Compass Pathways EV/EBIT

The EV/EBIT (Enterprise Value to EBIT) of Compass Pathways (CMPS) as of Sep 3, 2026 is -3.15. In the previous year, EV/EBIT (Enterprise Value to EBIT) was -3.17 — a change of -0.46% (higher).

EV/EBIT

-3.15

YoY

-0.46%

Last updated:

EV/EBIT (Enterprise Value to EBIT) of Compass Pathways is 2026 -3.15 . EV/EBIT (Enterprise Value to EBIT) of Compass Pathways was 2025 -3.17 . It decreases by -0.46% higher compared to the previous year.

The Compass Pathways EV/EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/EBIT
Date
EV/EBIT
Jan 1, 2019
-26.65 USD
Jan 1, 2020
-10.90 USD
Jan 1, 2021
-6.78 USD
Jan 1, 2022
-6.20 USD
Jan 1, 2023
-4.12 USD
Jan 1, 2024
-3.17 USD
Jan 1, 2025
-3.15 USD
Jan 1, 2026 (e)
-5.89 USD
The Compass Pathways EV/EBIT history
YEAREV/EBITYoY
est-5.89+86.81%
-3.15-0.46%
-3.17-23.17%
-4.12-33.47%
-6.20-8.65%
-6.78-37.76%
-10.90-59.11%
-26.65-40.97%
-45.15
Access this data via the Eulerpool API

Compass Pathways Valuation

Details

Historical Valuation Multiples

Price-to-Earnings Ratio (P/E)

The P/E ratio divides Compass Pathways's share price by its earnings per share. It tells you how many years of current earnings you are "paying for" when you buy the stock. A P/E of 20 means you pay $20 for every $1 of annual earnings. The S&P 500 historically trades at an average P/E of roughly 15–17. A P/E significantly above that may signal high growth expectations; one below may indicate undervaluation — or declining business quality.

Price-to-Sales Ratio (P/S)

The P/S ratio divides market capitalization by total revenue. Unlike the P/E ratio, it works even for companies that are not yet profitable, making it essential for evaluating high-growth firms. A P/S below 1.0 may indicate undervaluation, while ratios above 10 are typically reserved for fast-growing tech or SaaS companies with high expected future margins.

Price-to-EBIT Ratio

This ratio relates Compass Pathways's market price to its operating earnings, excluding the effects of debt structure and tax jurisdiction. It is particularly useful for comparing companies across different countries or with different levels of leverage, because it focuses purely on operational profitability. Lower values suggest cheaper operational earnings.

How to Use This Chart

This chart plots Compass Pathways's valuation multiples over time. Compare the current P/E, P/S, and P/EBIT to their own historical averages — if the current ratio is well below the multi-year average, the stock may be relatively cheap compared to its own track record. Combine this with industry comparisons: a P/E that looks high in absolute terms may be justified if Compass Pathways grows earnings faster than its peers.

Compass Pathways Stock analysis

What does Compass Pathways do? Compass Pathways PLC is a leading company specializing in the development of groundbreaking therapies for the treatment of mental illnesses. The company was founded in 2016 and is headquartered in London. Its goal is to revolutionize the treatment of depression and other mental illnesses. The business model of Compass Pathways is based on researching psychedelics as a potential treatment for patients suffering from severe depression and anxiety disorders. The company uses innovative approaches to precisely study the effects of psychedelics on the human brain and develop new therapy concepts and products from that. An important area of Compass Pathways is clinical research. The company collaborates closely with leading research institutions to understand the impacts of psychedelics on the human brain. The research results are then used to develop innovative methods for therapeutic use of psychedelics. Another important area of Compass Pathways is the development of therapeutic products. The company has developed a patented process for producing psilocybin, a substance found in hallucinogenic mushrooms. This process achieves a very high purity of the substance, enabling precise dosing and better control of its effects. The flagship product of Compass Pathways is COMP360, a medication based on psilocybin that is being developed for the treatment of depression. The medication is currently in clinical Phase 2 trials, showing promising results. If COMP360 receives approval, it has the potential to drastically change the way we treat depression. Compass Pathways is also active in other areas. The company conducts a range of research projects related to various psychedelic substances, including LSD and other hallucinogens. Another important area of Compass Pathways is training therapists and other professionals in the use of psychedelic substances. The company offers relevant courses to promote understanding of the therapeutic use of psychedelics and enable their safe and effective application for patient treatment. Overall, Compass Pathways is a company focused on the development of groundbreaking therapies for mental illnesses. Through combining cutting-edge research, innovative products, and professional education, the company has the potential to revolutionize the way we treat mental illnesses. Compass Pathways is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Compass Pathways stock

EV/EBIT (Enterprise Value to EBIT) of Compass Pathways is -3.15 in 2026.

EV/EBIT (Enterprise Value to EBIT) of Compass Pathways changed from -3.17 to -3.15, representing a -0.46% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EV/EBIT (Enterprise Value to EBIT) Compass Pathways since 2006 – with annual values, charts, and detailed analysis.

The EV/EBIT ratio measures a company's enterprise value relative to its operating earnings. It accounts for debt, making it useful for comparing companies with different capital structures.

EV/EBIT = Enterprise Value / Earnings Before Interest and Taxes

To evaluate EV/EBIT (Enterprise Value to EBIT)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/EBIT (Enterprise Value to EBIT).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/EBIT (Enterprise Value to EBIT)'s Compass Pathways with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

Valuation — Compass Pathways

All Key Metrics — Compass Pathways